ArticleJHEP reports : innovation in hepatology2025
Clinical burden of HDV in Spain: Incidence, prevalence, and associated comorbidities.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: HDV leads to the most severe form of viral hepatitis. It has been estimated to affect 5-13% of people who have chronic HBV worldwide. Evidence of HDV incidence, prevalence, and disease burden in Spain is limited. The purpose of this study is to evaluate the clinical burden of HDV in Spain by assessing the incidence, prevalence, and baseline demographics and comorbidities of patients with HDV infection compared with those with HBV monoinfection. Methods: Adults (≥18 years) with ≥1 International Classification of Disease-9/10-Clinical Modification diagnosis code for HDV or HBV in the Spanish National Health System's Hospital Discharge Records Database from January 1, 2000, to December 31, 2019, were identified. HDV prevalence and incidence were calculated. Baseline (duration before index disease) patient characteristics and comorbidities were assessed. Results: The estimated prevalence of adults with HDV infection among those with HBV was 4.9%, with an incidence of 4.5% over the study period. Adults with HDV infection were significantly younger than those with HBV monoinfection (mean [SD] age 42.7 [14.4] Conclusions: Adults with HDV infection who attended hospitals in Spain have a high comorbidity burden and conditions associated with potentially modifiable behaviors. Novel treatment strategies are needed to reduce morbidity rates among adults with HDV infection in Spain. Impacts and implications: Adults with HDV infection who attended hospitals in Spain had a high comorbidity burden and conditions associated with potentially modifiable behaviors (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.